SAB BIOTHERAPEUTICS, INC. Equity Securities, FV-NI, Gain (Loss)
SAB BIOTHERAPEUTICS, INC. (SABS) reported Equity Securities, FV-NI, Gain (Loss) of -$9.59 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-05-12
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was -$9.59K, a 1097.61% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $9.93K.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $62.83K.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-06-30 was -$3.73K, a 148.79% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for fiscal 2025 was $73.97K, a 184.49% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for fiscal 2024 was $26.00K.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$9.59K 10-Q · filed 2026-05-12 | $342.00 derived: sum of 2 quarters · filed 2026-05-12 | $63.17K derived: sum of 3 quarters · filed 2026-05-12 | $59.44K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $9.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $72.76K derived: sum of 2 quarters · filed 2026-03-09 | $69.03K derived: sum of 3 quarters · filed 2026-03-09 | $73.97K 10-K · filed 2026-03-09 |
| 2025-09-30 | $62.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $59.10K derived: sum of 2 quarters · filed 2025-11-14 | $64.04K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$3.73K 10-Q · filed 2025-08-07 | $1.21K 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $961.00 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $26.00K 10-K · filed 2025-03-31 | |||
| 2024-06-30 | $7.64K 10-Q · filed 2025-08-07 | $15.17K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $7.00K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |